Acadian Asset Management
CTKB icon

Acadian Asset Management’s Cytek Biosciences CTKB Stock Holding History

Acadian Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.74M Sell
398,988
-275,487
-41% -$1.3M ﹤0.01% 1000
2025
Q4 		$3.4M Buy
674,475
+108,902
+19% +$506K 0.01% 756
2025
Q3 		$1.96M Buy
565,573
+251,929
+80% +$946K ﹤0.01% 898
2025
Q2 		$1.06M Buy
313,644
+272,977
+671% +$910K ﹤0.01% 961
2025
Q1 		$162K Buy
+40,667
New +$211K ﹤0.01% 1288

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management's CTKB Position: Q1 2026 in Review

Acadian Asset Management reduced its Cytek Biosciences (CTKB) stake by 41% in Q1 2026, selling an estimated $1.3M and leaving 398,988 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

Acadian Asset Management first reported a position in CTKB in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.4M in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Acadian Asset Management held 398,988 shares of Cytek Biosciences worth $1.74M as of Q1 2026.
  • Acadian Asset Management sold 275,487 Cytek Biosciences shares in Q1 2026, an estimated $1.3M.
  • Cytek Biosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1000 holding.
  • Acadian Asset Management first reported a position in Cytek Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Acadian Asset Management's Cytek Biosciences position peaked at $3.4M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.